应用二甲双胍对糖尿病合并冠心病患者的脂肪因子chemerin水平影响的相关研究

A Related Study on the Effect of Metformin on the Level of Adipokines Chemerin in Patients with Diabetes and Coronary Heart Disease

目的分析二甲双胍对糖尿病合并冠心病患者的脂肪因子chemerin水平的影响。方法方便选取该院2016年3月—2018年12月收治的220例糖尿病合并冠心病患者纳入至该次研究,依照数字随机表法将其分为A组(110例)与B组(110例),A组接受二甲双胍片治疗,B组接受格列齐特缓释片治疗,均治疗10周,比较两组患者治疗前后的血糖、脂肪因子chemerin、炎性因子以及血脂水平。结果 B组的FBG(7.38±1.94)mmol/L、2 hFBG(8.97±1.49)mmol/L以及HbAlc水平(6.00±1.29)%显著高于A组(6.12±2.03)、(8.21±1.08)mmol/L、(5.43±1.21)%(t=4.706、4.331、3.380,P<0.05)。B组患者脂肪因子chemerin水平(252.73±24.36)ng/mL高于A组(212.54±17.21)ng/mL(t=14.118,P<0.05)。B组的IL-6(10.98±2.63)ng/L、TNF-α(47.82±6.13)ng/L明显高于A组(8.42±1.71)ng/L、(41.34±4.08)ng/L(t=8.559、9.230,P<0.05)。B组患者的HDL(1.07±0.11)mmol/L低于A组(1.23±0.14)mmol/L,TC(4.83±0.59)mmol/L、LDL(3.04±0.35)mmol/L、TG (2.98±1.04)mmol/L高于A组(4.42±0.41)mmol/L、(2.90±0.31)mmol/L、(2.46±0.93)mmol/L (t=9.425、5.985、3.141、3.909,P<0.05)。结论在糖尿病合并冠心病患者接受治疗的过程中,采用二甲双胍片的临床治疗效果较好,可显著控制患者的脂肪因子chemerin水平。

Objective To analyze the effect of metformin on the level of adipokine chemerin in patients with diabetes and coronary heart disease.Methods convenient selection 220 patients with diabetes and coronary heart disease admitted to the hospital from March 2016 to December 2018 were included in this study,and they were divided into group A(110 cases)and group B(110 cases)according to the number random table method group A received metformin tablets treatment,and group B received gliclazide sustained-release tablets treatment.Both groups were treated for 10 weeks.The blood glucose,adipokines chemerin,inflammatory factors and blood lipid levels of the two groups were compared before and after treatment.Results The FBG(7.38±1.94)mmol/L,2 hFBG(8.97±1.49)mmol/L and HbAlc levels(6.00±1.29)%of group B were significantly higher than those of group A(252.73±24.36),(8.21±1.08)mmol/L,(5.43±1.21)%(t=4.706,4.331,3.380,P<0.05).The level of adipokines chemerin in group B(152.73±24.36)ng/mL was higher than that in group A(212.54±17.21)ng/mL(t=14.118,P<0.05).IL-6(10.98±2.63)ng/L and TNF-α(47.82±6.13)ng/L in group B were significantly higher than those in group A(8.42±1.71)ng/L and(41.34±4.08)ng/L(t=8.559,9.230,P<0.05).The HDL(1.07±0.11)mmol/L of group B patients was lower than that of group A(1.23±0.14)mmol/L,while TC(4.83±0.59)mmol/L,LDL(3.04±0.35)mmol/L,TG(2.98±1.04)mmol/L were higher than group A(4.42±0.41)mmol/L,(2.90±0.31)mmol/L,(2.46±0.93)mmol/L(t=9.425,5.985,3.141,3.909,P<0.05).Conclusion In the course of treatment of patients with diabetes and coronary heart disease,the clinical treatment effect of metformin tablets is better,which can significantly control the level of adipokines chemerin in patients.